AstraZeneca ANDHI—Protocol D3250C00045 Evaluating the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment Ages 18 and older on a moderate to high dose of ICS with an additional controller therapy for 12 months (stable for 3 months) and 2 asthma exacerbations within the previous 12 month period; ACQ score of $1.5 at visit 1; screening pre-bronchodilator of < 80% and a serum eosinophil count of >300 cells/μL at visit 1 or 2. MUST remain at site for 2 hours post injection. (Length of trial = 24 weeks after randomization.) Compensation to subjects: $60 after each completed visit for a total of 11 visits.

BAXALTA 161406—A Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA: Ages $16 years and older who have been prescribed or started on Hyqvia. Visit will be coordinated with office visits and/or every 3 months. (Length of trial = 52 weeks, with the potential to continue for an additional year depending on blood results.) Compensation to participants: $25 after each completed visit.

Genentech GB39242--Protocol Title: GB39242: ASSESSING THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA Ages 18–75 years; (BMI) of 18–35 kg/m2 and weight $40 kg at screening; On ICS therapy at a total daily dose $500 μg of fluticasone propionate or equivalent plus at least one additional allowed controller medication, for $3 months prior to screening, with no changes within 4 weeks prior to screening; Documented history of at least one asthma exacerbation within 12 months prior to screening while on daily ICS maintenance therapy (same dose as at screening); Documented physician-diagnosed asthma for at least 12 months prior to screening Morning pre-bronchodilator FEV1 of 40%–80% of predicted at the screening and run-in (Week 0) visits. This sponsor is having a VERY difficult time enrolling globally. (Length of trial = 70 weeks, not including a 3 week run-in period) Compensation to participants: $75 after each completed visit or for 18 visits.

LeoPharma LP0162-1325 ECZTRA—Tralokinumab monotherapy for moderate-to-severe atopic dermatitis in subjects 18 years and older. Diagnosis of atopic dermatitis for $1 year. The trial is as follows: two screening visits with 20 weeks of double-blind Tralokinumab; followed by 34 weeks of open-label Tralokinumab treatment and a 16-week short-term extension period of open-label Tralokinumab and a FINAL follow-up visit. MULTIPLE skin scoring assessments at each visit preferably by the initial clinician. Compensation to participants: $75 after each completed visit, every 2 weeks (“potential” to have 39 total visits).